SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is trending after announcing a strategic partnership with Palantir and World View to develop AI-enabled multi-domain intelligence and defense platforms. The community is buzzing with excitement over this collaboration, anticipating a significant short squeeze and viewing it as a transformative catalyst for future growth in the autonomous systems sector.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines is trending following strong financial results and its emphasized growth as a domestic drone component producer, with the community actively discussing its strategic "picks and shovels" role within the surging defense sector and the government's Drone Dominance Program.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending as investors react to a new development agreement with Tower Semiconductor, which integrates the company's high-speed polymer modulator technology into a commercial silicon photonics platform. The community is focused on the potential for this partnership to accelerate mass-market adoption among major AI and data center suppliers, leading to intense debate over the stock's long-term commercialization timeline versus its current high-volume speculative momentum.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech Inc. (CITR) is experiencing a surge in attention and strong price momentum following its recent investor conference appearances and private meetings, which are increasing institutional visibility. The community is focused on the company's differentiated, EPA Safer Choice-recognized fire prevention technology and the significant market opportunity presented by escalating wildfire risks and tightening building codes.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively trending as investors weigh the upcoming R2 reveal against leaked pricing details, with the community split between bullish excitement over potential market share and bearish concerns regarding the long-term path to profitability. The conversation is dominated by debates over whether the new vehicle lineup's pricing and delivery timelines can effectively challenge established EV competitors in a volatile market environment.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending around its Investor Day, revealing plans for more affordable midsize EVs, autonomous driving, and robotaxi services aimed at long-term profitability. Community discussions are highly polarized, balancing optimism for potential future growth and a short squeeze against concerns about widening losses, significant cash burn, and the confirmed need for additional capital.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors digest news of a $2.25 billion acquisition of Kodiak Building Partners, with the community expressing optimism about the company's aggressive M&A strategy and potential for long-term growth. While some participants discuss short-term volatility and liquidity, the broader sentiment remains heavily focused on the leadership's execution track record and the expectation of future deal announcements.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is experiencing a surge in volume and price driven by growing investor confidence in its pivotal role as a supplier for Silicon Photonics and Co-Packaged Optics (CPO) solutions used in AI data centers. Community discussion is heavily focused on the company's technical partnerships and the potential for a long-term revenue inflection as these advanced optical components move toward commercial mass production.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending with high trading volume and call option activity, driven by anticipation for potential significant partnership or order announcements at the upcoming OFC Conference. The community is buzzing about POET's optical interposer technology as a crucial solution for energy-efficient, high-speed AI data centers, drawing comparisons to recent rallies in other photonics stocks.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors weigh its strong AI-driven cyber resilience narrative and potential for long-term growth against recent volatility that has hit the broader software and cybersecurity sectors. While the community remains divided over short-term price pressure and insider selling, many are actively discussing the stock as a prime candidate for a rebound, emphasizing that its fundamental role in data protection makes it a critical infrastructure play for the AI era.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VBIV Based on the following recent events, it seems like GSK is getting more serious about VBIV&#39;s CMV/GBM IP. IMO, these events could easily qualify GSK as an emerging candidate for a partnership for our CMV/Oncology IP or even as a potential acquirer.
  
a. GSK co-filing of a new US-20210069321 patent application with VBIV for the Immunotherapeutic Composition consists of our 1901 IP with GSK&#39;s adjuvant.

Investor

Brown Mamba

🖐️- SOME. 🔥🐻🔥

SephieV

S2H2

Jackson Card

Master of the Hum Hum Hum

AskSlapper

Wades World

Sy Huss

Cleo

Tobyornotoby

Adnan

Mr_Simpson

Pavel Hýža

Christopher Harvey

G37X

Nobody

Michal

Dmitry

RonBoBull

Mostly Equity

Jacob Knippenberg

ES Collier

OKGGG

john smith

StockTwits Web

VBI Vaccines Inc.

 Based on the following recent events, it seems like GSK is getting more serious about VBIV's CMV/GBM IP. IMO, these events could easily qualify GSK as an emerging candidate for a partnership for our CMV/Oncology IP or even as a potential acquirer.
  
a. GSK co-filing of a new US-20210069321 patent application with VBIV for the Immunotherapeutic Composition consists of our 1901 IP with GSK's adjuvant.

 b. The same patent was filed across three jurisdictions within a week apart from each other (Canada on March 8, 2021, the USA on March 10, 2021, and WO-Worldwide on March 17, 2021)

Emmo Silver

JGMoney

Ardesco

David

Armin

Maurizio (ita)

Mr Nguyen

Johnny

Fikret Mirzoyev

 c. Unlike VBIV&#39;s 1901 related IP patent US-20200376113, which was filed only in the US on December 3, 2020, the co-filed GSK patent goes into a full length, claiming the patent&#39;s applicability to other oncology indications such as breast, colon, ovarian, and prostate cancer, rhabdomyosarcoma, hepatocellular cancer, salivary gland tumors, neuroblastoma, and brain tumors.

 c. Unlike VBIV's 1901 related IP patent US-20200376113, which was filed only in the US on December 3, 2020, the co-filed GSK patent goes into a full length, claiming the patent's applicability to other oncology indications such as breast, colon, ovarian, and prostate cancer, rhabdomyosarcoma, hepatocellular cancer, salivary gland tumors, neuroblastoma, and brain tumors.

 Outlined claims of VBIV&#39;s US-20200376113 patent:

M. Finch

whynot2day

 Outlined claims of VBIV's US-20200376113 patent:

 Outlined claims of GSK&#39;s US-20210069321 patent for 1901 IP:

 Outlined claims of GSK's US-20210069321 patent for 1901 IP:

 d. The fact that Kirsten Schneider-Ohrum is listed on the patent as a co-inventor along with David, where she has no connection to neither underlying IP nor the GSK&#39;s AS01 adjuvant used in it, says a lot about this patent&#39;s intention.  IMO, the real purpose is an initiation of IP transfer from VBIV to GSK.

Jay Ell

BenjiCool

 d. The fact that Kirsten Schneider-Ohrum is listed on the patent as a co-inventor along with David, where she has no connection to neither underlying IP nor the GSK's AS01 adjuvant used in it, says a lot about this patent's intention.  IMO, the real purpose is an initiation of IP transfer from VBIV to GSK.

 e.  Also, Kirsten Schneider-Ohrum&#39;s sudden move from her previous position, where one of her responsibilities was enabling revenue growth by accurately forecasting the evolution of new vaccines and identifying profitable vaccines... now to head cytomegalovirus vaccine development bods well with the point d. above.

 e.  Also, Kirsten Schneider-Ohrum's sudden move from her previous position, where one of her responsibilities was enabling revenue growth by accurately forecasting the evolution of new vaccines and identifying profitable vaccines... now to head cytomegalovirus vaccine development bods well with the point d. above.

 f. The timing aspect of Kirsten Schneider-Ohrum&#39;s promotion (January of 2021) to head CMV-based vaccine development in correlation with our ongoing 1901 clinical trials&#39; positive progress right around the same time.

Karol Wy

 f. The timing aspect of Kirsten Schneider-Ohrum's promotion (January of 2021) to head CMV-based vaccine development in correlation with our ongoing 1901 clinical trials' positive progress right around the same time.

 g. VBIV&#39;s secrecy around undisclosed preclinical study for &quot;Other CMV+ Tumors&quot; paired with the points a. b. c. d. e. f. now starts making more sense.

Jefferson Carrol

 g. VBIV's secrecy around undisclosed preclinical study for "Other CMV+ Tumors" paired with the points a. b. c. d. e. f. now starts making more sense.

 h. GSK&#39;s recent ADR&#39;s issuance on March 15, 2021, and Automatic Shelf registration on March 26, 2021, might be a good indicator of them getting ready to finance upcoming partnership or BO.

 h. GSK's recent ADR's issuance on March 15, 2021, and Automatic Shelf registration on March 26, 2021, might be a good indicator of them getting ready to finance upcoming partnership or BO.

@bmkb24  I sent you a message in private chat.  You&#39;re definitely onto something... Thank you for this amazing post, ill read it again tomorrow AM and break it down with @ChugNorris

Mr. Investor

BioJoy

StockTwits For Android 

  I sent you a message in private chat.  You're definitely onto something... Thank you for this amazing post, ill read it again tomorrow AM and break it down with 

WEIBO

@bmkb24 you sir, are a blessing to this community. Thanks for this wonderful DD. Sure beats my speculative interpretation of common knowledge. GLTA.

 you sir, are a blessing to this community. Thanks for this wonderful DD. Sure beats my speculative interpretation of common knowledge. GLTA.

Clever Leaves Holdings Inc

@Xtrykr anytime brother, always happy to share my findings :)

Andrew

 anytime brother, always happy to share my findings :)

@bmkb24 I couldn&#39;t help but notice the filing date vs the publication dates where these patent applications were published within about 6-12 months of filing. That is very fast! Normally from filing to publishing takes 18 months. Was there some sort of priority given to these series of patents to have the patent office churn them out so quickly?

 I couldn't help but notice the filing date vs the publication dates where these patent applications were published within about 6-12 months of filing. That is very fast! Normally from filing to publishing takes 18 months. Was there some sort of priority given to these series of patents to have the patent office churn them out so quickly?

@Xtrykr it&#39;s quite possible that they applied for USPTO&#39;s prioritized examination path...

Joon

 it's quite possible that they applied for USPTO's prioritized examination path...

@bmkb24 @Xtrykr this would be a perfect scenario to an already perfect situation.

 this would be a perfect scenario to an already perfect situation.

AMC Entertainment Holdings

@bmkb24 $VBIV El, wow, thanks a lot, awesome and very telling find indeed! The joint GSK-VBIV US-20210069321 patent application has a filling date of Sep 8th, 2020. As you may remember, VBI Vaccines B.V. was registered in NL in the end of Oct 2020. These two events could be related. E.g., Tesaro BO by GSK also involved a Dutch incorporation of Tesaro two years before it has occurred.

 El, wow, thanks a lot, awesome and very telling find indeed! The joint GSK-VBIV US-20210069321 patent application has a filling date of Sep 8th, 2020. As you may remember, VBI Vaccines B.V. was registered in NL in the end of Oct 2020. These two events could be related. E.g., Tesaro BO by GSK also involved a Dutch incorporation of Tesaro two years before it has occurred.

@bmkb24 since the interview, news isn&#39;t their game plan.. important events such as their Israel client purchasing 1yr advance stock of HepB vaccines is significantly news worthy. They do not showcase either which and then they hit with events like CEPI, events with BRii etc ,  the IR of the company lags but still a great company to discover..

 since the interview, news isn't their game plan.. important events such as their Israel client purchasing 1yr advance stock of HepB vaccines is significantly news worthy. They do not showcase either which and then they hit with events like CEPI, events with BRii etc ,  the IR of the company lags but still a great company to discover..

Revive Therapeutics Ltd

@bmkb24 Thank you El! Some world-class DD.  Not worried about this low volume bio SP bleed, but your posts always make the dreary days much better. Thanks bro.

Stephanie

Sam The Seed

 Thank you El! Some world-class DD.  Not worried about this low volume bio SP bleed, but your posts always make the dreary days much better. Thanks bro.

Biocryst Pharmaceuticals Inc.

Advanced Micro Devices Inc

SPDR S&P Biotech ETF

TG Therapeutics Inc

Robinhood Markets Inc

DraftKings Inc

CoreWeave Inc

Brunt - F.C.A.

@bmkb24 best DD I have seen on here in a while thank you!

StockTwits for iOS

 best DD I have seen on here in a while thank you!

Ault Alliance Inc

John Daugherty

@stau Anytime bro. Btw, excellent association with the B.V. event... Another similarity with the Tesaro acquisition is that in the same year of that BO, GSK initiated automatic shelf registration F-3ASR on March 27, 2018, followed by the cascade of other prospectus-based filings to help raise cash. Here is the chronological list of those filings, starting with the March 27 shelf registration filing and ending with the tender drop on  on December 3, 2018.

$VBIV Don&#39;t let them steal your shares. Extremely bullish.

 Anytime bro. Btw, excellent association with the B.V. event... Another similarity with the Tesaro acquisition is that in the same year of that BO, GSK initiated automatic shelf registration F-3ASR on March 27, 2018, followed by the cascade of other prospectus-based filings to help raise cash. Here is the chronological list of those filings, starting with the March 27 shelf registration filing and ending with the tender drop on  on December 3, 2018.

@bmkb24 Thank you for the update and condensation of information. I wouldn&#39;t have had the chance at all or experience to get something like this together. CHeers

 Thank you for the update and condensation of information. I wouldn't have had the chance at all or experience to get something like this together. CHeers

Energy Fuels Inc

@bmkb24  Thanks for sharing your hard work.

ImmunityBio Inc

@C0ffeeB34n @glimdbea anytime guys, always happy to share :)

Although GSK does not actively pursue any CMV IP after they put a halt on the one they had due to insufficient efficacy... The recent activity around hiring/promoting senior CMV personnel is very telling. 

Senior Director, Clinical Development Vaccines - Cytomegalovirus
https://jobs.gsk.com/en-gb/jobs/273700?lang=en-us

Although GSK does not actively pursue any CMV IP after they put a halt on the one they had due to insufficient efficacy... The recent activity around hiring/promoting senior CMV personnel is very telling. 

Senior Director, Clinical Development Vaccines - Cytomegalovirus


@bmkb24 El, I found that in June 2020 GSK has submitted another patent regarding the use of the CHO mammalian cells for production CMV antigens (and which was published in Sep 2020):
https://www.lens.org/lens/patent/170-868-410-347-228

The Lens serves almost all the patents and scholarly work in the world as a free, open and secure digital public good, with user privacy a paramount focus.

The Lens - Free & Open Patent and Scholarly Search

HR P20200932 T1 - Mammalian Cells Expressing Cytomegalovirus Antigens The Lens - Free & Open Patent and Scholarly Search

 El, I found that in June 2020 GSK has submitted another patent regarding the use of the CHO mammalian cells for production CMV antigens (and which was published in Sep 2020):
